News and Updates
ChromaCode's Latest Innovations

Publications at ChromaCode - close up of three scientists in a lab

ChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSCLC Assay in the U.S.

Street Insider: CARLSBAD, Calif., Aug. 10, 2023 /PRNewswire/ — ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients, and physicians, today announced a strategic partnership with Protean BioDiagnostics Inc., a CAP/CLIA-accredited, high-complexity laboratory specializing in developing and commercializing

Read More »

ChromaCode Non-Small-Cell Lung Cancer Assay

360Dx: ChromaCode has launched a non-small-cell lung cancer (NSCLC) assay based on its High Definition PCR (HDPCR) technology for early-access customers. The assay panel detects actionable NSCLC variants in nine relevant genes using amplitude modulation and multi-spectral encoding. It requires low sample

Read More »

ChromaCode commercially launches HDPCR-based NSCLC assay

Medical Device Network: The assay leverages amplitude modulation and multi-spectral encoding to identify actionable NSCLC variants in nine relevant genes. Genomics multiplexing platform company ChromaCode has commercially introduced the High Definition PCR (HDPCR)-based non-small-cell lung cancer (NSCLC) assay. Leveraging amplitude modulation

Read More »

Six molecular diagnostics companies to watch

Labiotech: You may have heard of the enzyme-linked immunosorbent assay, more commonly known as the ELISA test, which is used to measure molecules like antibodies, antigens and proteins in biological samples. Used to diagnose infections caused by human immunodeficiency viruses

Read More »